Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 311

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 2
Chunk 311
---
5 as compared to $0
during the three months ended September 30, 2024.

Net loss and net loss attributable to common
stockholders

For the three months ended September 30, 2025 and 2024, net loss amounted
to $4,856,000 and $4,228,000, respectively, which represents an increase in net loss of $628,000, or 14.9%. During the three months ended
September 30, 2025, in connection with our Series D Preferred Stock down round triggering event, we recorded deemed dividends of $6,650,000.
Accordingly, for the three months ended September 30, 2025 and 2024, net loss attributable to common stockholders amounted to $11,506,000,
or $(9.10) per common share, and $4,228,000, or $(170.22) per common share, respectively.

39

Results of Operations for the Nine Months
Ended September 30, 2025 and 2024

The results of operations
for the nine months ended September 30, 2024 are pro forma as the period presented in the following table and discussion includes
the Predecessor for the period from January 1, 2024 through February 13, 2024 and the Company for the period from February 14, 2024 through
September 30, 2024. This pro forma period from January 1, 2024 to September 30, 2024 does not include the Merger transactions that occurred
on-the-line.

    For the Nine Months Ended September 30,  

    2024  

    2025  (Successor)  
    (Pro forma) (Predecessor  and Successor)  
    Difference  
    Percentage Change 
  
    Operating expenses: 

    Research and development 
    $8,048,034  
    $6,156,761  
    $1,891,273  
     30.7%
  
    General and administrative 
     5,988,867  
     7,945,784  
     (1,956,917) 
     (24.6)%
  
    Total operating expenses 
     14,036,901  
     14,102,545  
     (65,644) 
     (0.5)%